---
title: "Xingqi Pharmaceutical: Net profit in the first half of 2025 increased by 97.75% year-on-year, plans to distribute 7 yuan for every 10 shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254789920.md"
description: "Xingqi Pharmaceutical announced that in the first half of 2025, operating revenue reached 1.163 billion yuan, a year-on-year increase of 30.38%. Net profit was 335 million yuan, a year-on-year increase of 97.75%. It plans to distribute a cash dividend of 7 yuan for every 10 shares to all shareholders"
datetime: "2025-08-27T11:03:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254789920.md)
  - [en](https://longbridge.com/en/news/254789920.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254789920.md)
generator: "portal-rs"
---

# Xingqi Pharmaceutical: Net profit in the first half of 2025 increased by 97.75% year-on-year, plans to distribute 7 yuan for every 10 shares

Xingqi Pharmaceutical announced that in the first half of 2025, operating revenue was 1.163 billion yuan, a year-on-year increase of 30.38%. Net profit was 335 million yuan, a year-on-year increase of 97.75%. It plans to distribute a cash dividend of 7 yuan for every 10 shares to all shareholders

### Related Stocks

- [300573.CN](https://longbridge.com/en/quote/300573.CN.md)

## Related News & Research

- [REG - Origin Enterprises - Holding(s) in Company](https://longbridge.com/en/news/296240027.md)
- [Lundbeck Foundation unit Lundbeckfond Invest launches voluntary exchange offer for Lundbeck A-shares](https://longbridge.com/en/news/296304407.md)
- [Buick launches Electra L7 BEV in China, starting at $25,000 with 702-km range](https://longbridge.com/en/news/296330854.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)
- [More than 20,000 off-road motorcycles recalled over dangerous brake defect that could lead to death](https://longbridge.com/en/news/296556254.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**